Finance

FDA nod for Icotyde could reshape psoriasis market

According to Benzinga's notes, the FDA approved Icotyde (icotrokinra), an IL-23 receptor antagonist oral pill for adults with moderate-to-severe plaque psoriasis and patients aged 12+, in a Johnson & Johnson–Protagonist Therapeutics collaboration. Independent verification is pending, but the move could tilt competition toward J&J by adding an oral IL-23R option and pressuring AbbVie's Skyrizi.

📅 March 19, 2026
⏱️ 2 min read
FDA nod for Icotyde could reshape psoriasis market

Key Takeaways

  • FDA approval would trigger a $50 million milestone payment to Protagonist on approval.
  • The deal allows for up to $580 million in additional regulatory and sales milestones.
  • The Phase 3 ICONIC program included about 2,500 patients.
  • J&J holds exclusive worldwide rights to develop Icotyde in Phase 2 and beyond, with commercial rights to derivatives.
  • Icotyde could redefine psoriasis competition by adding an oral IL-23R option, potentially pressuring AbbVie's Skyrizi.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Johnson & Johnson Pharmaceutical company; collaboration partner for Icotyde
  • Protagonist Therapeutics Biotech partner; recipient of milestones and royalties
  • AbbVie Pharmaceutical company; competitor with Skyrizi

MarketMoodz Analysis

For investors, the approval could unlock milestone upside for Protagonist and strengthen J&J's dermatology pipeline, while adding an oral IL-23R option to a portfolio historically dominated by biologics. The $50 million upfront milestone and up to $580 million in potential regulatory and sales milestones create meaningful optionality tied to approval, labeling, and launch milestones.

If the deal terms hold, Icotyde could shift the competitive landscape against AbbVie by expanding the oral-IL-23 class. The market has already rewarded oral candidates for their convenience and potential adherence benefits, which could translate into share gains if Icotyde shows favorable safety and real-world performance, potentially expanding the total addressable psoriasis market beyond current penetration.

What to watch next includes verifying the contract terms in official filings or press releases, monitoring regulatory labeling and safety signals, and assessing the timing and market reception of a potential Icotyde launch across adults and adolescents.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial